|
HY-D0934-10mg
|
MedChemexpress LLC
|
(5)6-Carboxytetramethylrhodamine [CAS 117557-83-2]
|
|
|
|
|
HY-D0934-5mg
|
MedChemexpress LLC
|
(5)6-Carboxytetramethylrhodamine [CAS 117557-83-2]
|
|
|
|
|
HY-P99353-1mg
|
MedChemexpress LLC
|
Ascrinvacumab [CAS 1463459-96-2]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99353-10mg
|
MedChemexpress LLC
|
Ascrinvacumab [CAS 1463459-96-2]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99353-5mg
|
MedChemexpress LLC
|
Ascrinvacumab [CAS 1463459-96-2]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99236-1mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99236-10mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99236-5mg
|
MedChemexpress LLC
|
Bexmarilimab [CAS 2259301-27-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99257-1mg
|
MedChemexpress LLC
|
Bleselumab [CAS 1453067-91-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99257-10mg
|
MedChemexpress LLC
|
Bleselumab [CAS 1453067-91-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99257-5mg
|
MedChemexpress LLC
|
Bleselumab [CAS 1453067-91-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99485-1mg
|
MedChemexpress LLC
|
Brazikumab [CAS 1610353-18-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99485-10mg
|
MedChemexpress LLC
|
Brazikumab [CAS 1610353-18-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99485-5mg
|
MedChemexpress LLC
|
Brazikumab [CAS 1610353-18-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9971-1mg
|
MedChemexpress LLC
|
Camrelizumab [CAS 1798286-48-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P9971-5mg
|
MedChemexpress LLC
|
Camrelizumab [CAS 1798286-48-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P9905-1mg
|
MedChemexpress LLC
|
Cetuximab [CAS 205923-56-4]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9905-25mg
|
MedChemexpress LLC
|
Cetuximab [CAS 205923-56-4]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9905-5mg
|
MedChemexpress LLC
|
Cetuximab [CAS 205923-56-4]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9905-50mg
|
MedChemexpress LLC
|
Cetuximab [CAS 205923-56-4]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99827-1mg
|
MedChemexpress LLC
|
Cobolimab [CAS 2022215-65-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P99827-10mg
|
MedChemexpress LLC
|
Cobolimab [CAS 2022215-65-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P99827-5mg
|
MedChemexpress LLC
|
Cobolimab [CAS 2022215-65-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P99260-1mg
|
MedChemexpress LLC
|
ConatuMu mab [CAS 896731-82-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99260-10mg
|
MedChemexpress LLC
|
ConatuMu mab [CAS 896731-82-1]
|
|
Cancer-programmed cell death
|
|
